PE20230825A1 - Inhibidores de kras triciclicos fusionados - Google Patents

Inhibidores de kras triciclicos fusionados

Info

Publication number
PE20230825A1
PE20230825A1 PE2022002194A PE2022002194A PE20230825A1 PE 20230825 A1 PE20230825 A1 PE 20230825A1 PE 2022002194 A PE2022002194 A PE 2022002194A PE 2022002194 A PE2022002194 A PE 2022002194A PE 20230825 A1 PE20230825 A1 PE 20230825A1
Authority
PE
Peru
Prior art keywords
alkenyl
alkyl
compound
kras
tricyclic
Prior art date
Application number
PE2022002194A
Other languages
English (en)
Inventor
Wenyu Zhu
xiaozhao Wang
Artem Shvartsbart
Wenqing Yao
Chao Qi
Rocco Policarpo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20230825A1 publication Critical patent/PE20230825A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Referido a un compuesto de formula (I), o una de sus sales farmaceuticamente aceptables; en donde: cada linea segmentada representa un enlace simple o un enlace doble; X es N o CR7; Y es N o C; R1 se selecciona de H, D, alquilo C1-6, alquenilo C2-6, entre otros; R2 se selecciona de H, alquilo C1-6, alquenilo C2-6, entre otros; Cy1 se selecciona de cicloalquilo C3-10, heterocicloalquilo de 4-10 miembros, arilo C6-10 y heteroarilo de 5-10 miembros; R3 se selecciona de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, entre otros; R4 se selecciona de H, D, alquilo C1-6, alquenilo C2-6, entre otros; R5 se selecciona de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, entre otros; R6 se selecciona de H, alquilo C1-6, alquenilo C2-6, entre otros; Cy2 se selecciona de cicloalquilo C3-10, heterocicloalquilo 4-14 miembros, arilo C6-10 y heteroarilo de 5-10 miembros. Un compuesto seleccionado es 1-(4-(8-cloro-6-fluoro-7-(3-hidroxinaftalen-1-il)-1H-pirazolo[4,3-c]-quinolin-1-il)-piperidin-1-il)prop-2-en-1-ona. Estos compuestos son inhibidores de KRAS triciclicos fusionados. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto y un metodo para inhibir la actividad de KRAS, y su uso para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, como el cancer.
PE2022002194A 2020-04-16 2021-04-15 Inhibidores de kras triciclicos fusionados PE20230825A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011089P 2020-04-16 2020-04-16
US202163146899P 2021-02-08 2021-02-08
PCT/US2021/027513 WO2021211864A1 (en) 2020-04-16 2021-04-15 Fused tricyclic kras inhibitors

Publications (1)

Publication Number Publication Date
PE20230825A1 true PE20230825A1 (es) 2023-05-19

Family

ID=75870725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002194A PE20230825A1 (es) 2020-04-16 2021-04-15 Inhibidores de kras triciclicos fusionados

Country Status (16)

Country Link
US (1) US20210355121A1 (es)
EP (1) EP4135844A1 (es)
JP (1) JP2023522202A (es)
CN (1) CN115702025A (es)
AU (1) AU2021254794A1 (es)
BR (1) BR112022020841A2 (es)
CA (1) CA3179692A1 (es)
CL (2) CL2022002828A1 (es)
CO (1) CO2022016377A2 (es)
CR (1) CR20220584A (es)
EC (1) ECSP22087539A (es)
IL (1) IL297165A (es)
MX (1) MX2022012780A (es)
PE (1) PE20230825A1 (es)
TW (1) TW202204355A (es)
WO (1) WO2021211864A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
BR112022003543A2 (pt) 2019-08-29 2022-05-24 Array Biopharma Inc Inibidores de kras g12
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
US20230143938A1 (en) * 2021-10-01 2023-05-11 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) * 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
CN115317490A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 化合物bml-275在制备改善鼻咽癌预后的药物中的应用
CN114394967B (zh) * 2022-01-28 2023-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种2-吡唑苯胺与1,3-二羰基化合物合成吡唑并喹啉衍生物的方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20240101557A1 (en) * 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20040089753A1 (en) 2000-06-28 2004-05-13 Holland Simon Joseph Wet milling process
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
CN101945867A (zh) 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
LT4209510T (lt) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
HUE030714T2 (en) 2010-10-25 2017-05-29 G1 Therapeutics Inc CDK inhibitors
CN102655637A (zh) * 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信***和组网方法
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
EP2769980B1 (en) * 2011-10-07 2016-02-03 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivative as pde9 inhibitors
AU2016244017B2 (en) * 2015-04-03 2020-07-23 Nant Holdings Ip, Llc Compositions and methods of targeting mutant K-ras
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
GEP20227419B (en) 2015-07-30 2022-10-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
AU2016355433C1 (en) * 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
MX2018006207A (es) 2015-11-19 2018-09-05 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
EA201891494A1 (ru) 2015-12-22 2019-01-31 Инсайт Корпорейшн Гетероциклические соединения в качестве иммуномодуляторов
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
KR20190111025A (ko) 2016-12-22 2019-10-01 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
JP7351850B2 (ja) * 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３修飾因子
SG11202011165TA (en) 2018-05-11 2020-12-30 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EP3837014B1 (en) * 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators

Also Published As

Publication number Publication date
JP2023522202A (ja) 2023-05-29
BR112022020841A2 (pt) 2023-05-02
MX2022012780A (es) 2023-01-18
CL2023002090A1 (es) 2023-12-15
CR20220584A (es) 2023-02-15
IL297165A (en) 2022-12-01
US20210355121A1 (en) 2021-11-18
CA3179692A1 (en) 2021-10-21
ECSP22087539A (es) 2023-01-31
WO2021211864A1 (en) 2021-10-21
CL2022002828A1 (es) 2023-03-31
CO2022016377A2 (es) 2023-02-27
CN115702025A (zh) 2023-02-14
TW202204355A (zh) 2022-02-01
AU2021254794A1 (en) 2022-12-15
EP4135844A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20221905A1 (es) Aminas biciclicas como inhibidoras de la cdk2
AR041740A1 (es) Derivados de dihidropirimido [4,5-d] pirimidona sustituida por amino. metodo de obtencion y su uso como inhibidor de proteinquinasas
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP22012347A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
AR036106A1 (es) Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
AR051686A1 (es) Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4.
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR052413A1 (es) Nuevos derivados de piridotienopiriidina
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2021013224A (es) Pirrolopiridinas sustituidas como inhibidores de jak.
CL2004000226A1 (es) Compuestos derivados de [4-amino-2-((cicloalquilo, heterociclo)-amino)-pirimidin-5-il]-(arilo, heteroarilo, cicloalquilo o heterociclo)metanoma, inhibidores de quinasas ciclina-dependientes, en particular de (cdk4); proceso de preparacion; compuesto
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones